ERAS - NASDAQ
Erasca, Inc.
$13.18
+1.2%Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. It is also developing ERAS-801, a central nervous system-penetrant EGFR inhibitor for the treatment of patients with recurrent glioblastoma multiforme. The company was incorporated in 2018 and is headquartered in San Diego, California.
At a Glance
Live SnapshotErasca, Inc. Management Team
Dr. Michael D. Varney Ph.D.
Chairman of Research & Development, Scientific Advisory Board Member and Director
Compensation
$89,593
Dr. David M. Chacko M.D.
Chief Financial Officer & Chief Business Officer
Compensation
$728,816
Dr. Shannon R. Morris M.D., Ph.D.
Chief Medical Officer
Compensation
$720,640
Dr. Nik Chetwyn Ph.D.
Chief Operating Officer
Dr. Lisa Tesvich-Bonora Ph.D.
Chief People Officer
Ms. Chandra D. Lovejoy M.S.
Chief Regulatory Affairs Officer
Dr. Jonathan E. Lim M.D.
Co-Founder, Chairman & Chief Executive Officer
Compensation
$1,099,724
Mr. Ebun S. Garner Esq., J.D.
General Counsel & Corporate Secretary
Compensation
$607,440
Mr. Brian L. Baker CPA, M.S.
Senior Vice President of Finance
Dr. Robert Shoemaker Ph.D.
Senior Vice President of Research
Erasca, Inc. Insider Positioning
During the last 12 months, insiders have purchased $1.22M and sold $2.28M worth of ERAS shares, resulting in $1.07M of net selling activity.
3 Months
0
0.00
80.0K
1.31M
-1.3M
-$1.31M
3-6 Months
0
0.00
140.0K
971.57K
-972K
-$972K
6-9 Months
0
0.00
0
0.00
+0
+$0
9-12 Months
840.0K
1.22M
0
0.00
+1.2M
+$1.22M
Top Buyers
Start Valerie Denise Harding
Director
$174K
Multani Pratik S
Director
$174K
Bristol James Arthur
Director
$174K
Casdin Alexander W.
Director
$174K
Varney Michael David
Director
$174K
Top Sellers
Garner Ebun
Officer: Chief Legal Officer
$1.98M
Morris Shannon
Officer: Chief Medical Officer
$301K
Insider Activity Analysis
Net Insider Sentiment
Slightly bearish with $1.07M net selling. Selling modestly exceeds buying, which could be routine diversification rather than concern.
Buy/Sell Ratio
Moderately negative ratio. Selling is roughly double the buying, which may be routine or signal caution.
Recent Trend (3 Months)
Heavy recent selling activity. Recent insider sales notably exceed purchases—may warrant investigation into company developments.
Insider Participation
5 insider buyers vs. 2 sellers. Broad-based buying across management team suggests widespread confidence.
SEC Filings
ERAS - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | April 28, 2026 | June 26, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | April 29, 2025 | June 24, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | April 26, 2024 | June 20, 2024 | 2024 | |
DEF 14A DEF 14A 2023 N/A | April 28, 2023 | June 22, 2023 | 2023 | |
DEF 14A DEF 14A 2022 N/A | April 28, 2022 | June 22, 2022 | 2022 |
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.